Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AKTX vs PRTO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AKTX Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 7–1 Matrix Metrics)

AKTX Overall Winner 6-Pillar Tally: AKTX 2 – 1 PRTO (3 Tie) Matrix Metrics: AKTX 7 – 1 PRTO

As of Nov 20, 2026, Akari Therapeutics plc (AKTX) is the stronger overall head-to-head candidate over PRTO (PRTO) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). AKTX carries a Unified Composite Score of 50.1/100 (HOLD) at $7.18 (N/M Forward P/E, 0.0% operating margin), whereas PRTO carries 33.3/100 (SELL) at $24.45 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: AKTX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.3); meanwhile PRTO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AKTX vs PRTO
AKTX NASDAQ Head-to-Head Winner
Akari Therapeutics plc ADR (0.01 USD)
Pharmaceutical Preparations
$7.18
+7.0% 1D
Market Cap $15.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 77.35β · 143% Vol
Unified Composite Score
50.1 / 100 HOLD
Tech 65.0 Fund 56.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.3 · SMA20: $7.52 · SMA50: $8.48
PRTO US Equity
PRTO
Institutional Equity
$24.45
-3.36% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.89β · 21% Vol
Unified Composite Score
33.3 / 100 SELL
Tech 12.0 Fund 36.0 Flow 50.0 Mom 34.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.3%), weak momentum, RSI 23
RSI-14: 22.6 · SMA20: $26.61 · SMA50: $27.03

6-Pillar Scorecard Institutional Category Breakdown (AKTX 2 – 1 PRTO)

Columns: Metric · AKTX · PRTO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale AKTX
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A N/A
Market Cap $15.6M N/A
3. Profitability & Quality AKTX
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -146.3% N/A
4. Balance Sheet & Cash Flow PRTO
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $7.66 Book/Sh · -146.3% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AKTX (7) vs PRTO (1)
Institutional Metric AKTX PRTO Criterion Row Edge
Market Capitalization
Scale
$15.6M N/A Larger Scale AKTX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth AKTX
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin AKTX
Net Profit Margin
Profitability
0.0% N/A Higher Margin AKTX
Return on Equity (ROE)
Capital Efficiency
-146.3% N/A Higher ROE AKTX
52-Week Range Position
Momentum
24% ($0–$29) 0% ($24–$29) Stronger Trend AKTX
Beta / 30D Volatility
Risk Regime
77.35β · 143% Vol 0.89β · 21% Vol Lower Realized Risk PRTO
Unified Institutional Score
Composite Signal
50.1 / 100 (HOLD) 33.3 / 100 (SELL) Higher Composite AKTX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($7.66 Book/Sh · -146.3% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PRTO +1.8 pp
AKTX: -11.36% · PRTO: -9.56%
3M Horizon AKTX +5.77 pp
AKTX: -8.54% · PRTO: -14.31%
6M Horizon AKTX +51.1 pp
AKTX: +39.69% · PRTO: -11.41%
1Y Horizon AKTX +5159.61 pp
AKTX: +5156.22% · PRTO: -3.39%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKTX vs PRTO. Trailing 12-month operating profitability (AKTX 0.0% vs PRTO N/A) and valuation multiples (AKTX N/M vs PRTO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AKTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-146.3% · N/M
PRTO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AKTX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PRTO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PRTO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AKTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PRTO Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AKTX vs PRTO Key Questions & Quantitative Answers

As of Nov 20, 2026, Akari Therapeutics plc (AKTX) is the stronger overall head-to-head candidate over PRTO (PRTO) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). AKTX carries a Unified Composite Score of 50.1/100 (HOLD) at $7.18 (N/M Forward P/E, 0.0% operating margin), whereas PRTO carries 33.3/100 (SELL) at $24.45 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: AKTX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.3); meanwhile PRTO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AKTX leads the Growth & Scale pillar: AKTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PRTO at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, AKTX generates N/A in USD-normalized revenue versus N/A for PRTO. In operating R&D and SG&A reinvestment, AKTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PRTO.

AKTX and PRTO trade at balanced relative valuation multiples. AKTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PRTO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKTX (-146.3% ROE) versus PRTO (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, AKTX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (77.35β · 143% Vol realized risk). By comparison, PRTO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.89β · 21% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.